Promoting innate immunity through pyroptosis induction or cGAS‐STING pathway activation has emerged as a potent approach to counteract the immunosuppressive tumor microenvironment and elicit systemic antitumor immunity. However, current pyroptosis inducers and STING agonists often suffer from limitations including instability, unpredictable side effects, or inadequate intracellular expression of gasdermin and STING. Here, a tumor‐specific nanotheranostic platform that combines photodynamic therapy (PDT) with epigenetic therapy to simultaneously activate pyroptosis and the cGAS‐STING pathway in a light‐controlled manner is constructed. This approach involves the development of oxidation‐sensitive nanoparticles (NP1) loaded with the photosensitizer TBE, along with decitabine liposomes (NP2). NP2 enables the restoration of STING and GSDME expression, while NP1‐mediated PDT facilitates the release of DNA fragments from damaged mitochondria to potentiate the cGAS‐STING pathway, and promotes the activation of caspase‐3 to cleave the upregulated GSDME into pore‐forming GSDME‐N terminal. Subsequently, the released inflammatory cytokines facilitate the maturation of antigen‐presentation cells, triggering T cell‐mediated antitumor immunity. Overall, this study presents an elaborate strategy for simultaneous photoactivation of pyroptosis and the cGAS‐STING pathway, enabling targeted photoimmunotherapy in immunotolerant tumors. This innovative approach holds significant promise in overcoming the limitations associated with existing therapeutic modalities and represents a valuable avenue for future clinical applications.This article is protected by copyright. All rights reserved